WO2002032375A3 - Uses of monoclonal antibody 8h9 - Google Patents
Uses of monoclonal antibody 8h9 Download PDFInfo
- Publication number
- WO2002032375A3 WO2002032375A3 PCT/US2001/032565 US0132565W WO0232375A3 WO 2002032375 A3 WO2002032375 A3 WO 2002032375A3 US 0132565 W US0132565 W US 0132565W WO 0232375 A3 WO0232375 A3 WO 0232375A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- monoclonal antibody
- provides
- derivative
- binding
- tumor cells
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- 230000000295 complement effect Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
- C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002423843A CA2423843A1 (en) | 2000-10-18 | 2001-10-18 | Uses of monoclonal antibody 8h9 |
AU2002215383A AU2002215383A1 (en) | 2000-10-18 | 2001-10-18 | Uses of monoclonal antibody 8h9 |
EP01983999A EP1399187A4 (en) | 2000-10-18 | 2001-10-18 | Uses of monoclonal antibody 8h9 |
US10/097,558 US7737258B2 (en) | 2000-10-18 | 2002-03-08 | Uses of monoclonal antibody 8H9 |
CA2463017A CA2463017C (en) | 2001-10-17 | 2002-10-17 | Method for preparation of single chain antibodies |
EP02801782A EP1441765A4 (en) | 2001-10-17 | 2002-10-17 | Method for preparation of single chain antibodies |
US10/273,762 US7666424B2 (en) | 2001-10-17 | 2002-10-17 | Methods of preparing and using single chain anti-tumor antibodies |
AU2002362846A AU2002362846A1 (en) | 2001-10-17 | 2002-10-17 | Method for preparation of single chain antibodies |
PCT/US2002/033331 WO2003033670A2 (en) | 2001-10-17 | 2002-10-17 | Method for preparation of single chain antibodies |
US10/505,658 US7740845B2 (en) | 2000-10-18 | 2003-03-06 | Uses of monoclonal antibody 8H9 |
US12/709,848 US8148154B2 (en) | 2001-10-17 | 2010-02-22 | Method for preparation of single chain antibodies |
US12/721,798 US8414892B2 (en) | 2000-10-18 | 2010-03-11 | Uses of monoclonal antibody 8H9 |
US12/797,081 US8501471B2 (en) | 2000-10-18 | 2010-06-09 | Uses of monoclonal antibody 8H9 |
US13/858,234 US9062110B2 (en) | 2000-10-18 | 2013-04-08 | Uses of monoclonial antibody 8H9 |
US13/958,902 US20140161814A1 (en) | 2000-10-18 | 2013-08-05 | Uses of monoclonal antibody 8h9 |
US15/365,803 US9938351B2 (en) | 2000-10-18 | 2016-11-30 | Uses of monoclonal antibody 8H9 |
US15/899,801 US20180208673A1 (en) | 2000-10-18 | 2018-02-20 | Uses of monoclonal antibody 8h9 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24134400P | 2000-10-18 | 2000-10-18 | |
US60/241,344 | 2000-10-18 | ||
US33039601P | 2001-10-17 | 2001-10-17 | |
US60/330,396 | 2001-10-17 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/982,645 Continuation-In-Part US20020102264A1 (en) | 2000-10-18 | 2001-10-18 | Uses of monoclonal antibody 8H9 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/097,558 Continuation-In-Part US7737258B2 (en) | 2000-10-18 | 2002-03-08 | Uses of monoclonal antibody 8H9 |
US10/273,762 Continuation-In-Part US7666424B2 (en) | 2000-10-18 | 2002-10-17 | Methods of preparing and using single chain anti-tumor antibodies |
Publications (4)
Publication Number | Publication Date |
---|---|
WO2002032375A2 WO2002032375A2 (en) | 2002-04-25 |
WO2002032375A3 true WO2002032375A3 (en) | 2002-06-20 |
WO2002032375A8 WO2002032375A8 (en) | 2002-09-12 |
WO2002032375A9 WO2002032375A9 (en) | 2003-01-03 |
Family
ID=26934217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/032565 WO2002032375A2 (en) | 2000-10-18 | 2001-10-18 | Uses of monoclonal antibody 8h9 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1399187A4 (en) |
CA (1) | CA2423843A1 (en) |
WO (1) | WO2002032375A2 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7737258B2 (en) * | 2000-10-18 | 2010-06-15 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
US7666424B2 (en) | 2001-10-17 | 2010-02-23 | Sloan-Kettering Institute For Cancer Research | Methods of preparing and using single chain anti-tumor antibodies |
IL165364A0 (en) | 2002-05-28 | 2006-01-15 | Omrix Biopharmaceuticals Inc | Method for obtaining anti-idiotype antibodies |
CA2490399C (en) | 2002-06-19 | 2015-10-06 | Raven Biotechnologies, Inc. | Novel raag10 cell surface target and a family of antibodies recognizing that target |
EP1567556A4 (en) * | 2002-12-02 | 2006-03-22 | Us Gov Health & Human Serv | Recombinant immunotoxin and use in treating tumors |
US6987270B2 (en) | 2003-05-07 | 2006-01-17 | General Electric Company | Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes |
ES2381557T3 (en) | 2004-08-03 | 2012-05-29 | Innate Pharma | Therapeutic and diagnostic methods and compositions to determine 4IG-B7-H3 and its homologous receptor in NK cells |
AU2010282340B2 (en) | 2009-08-13 | 2016-12-22 | The Johns Hopkins University | Methods of modulating immune function |
AU2011223782B2 (en) | 2010-03-04 | 2014-09-18 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
KR20160135190A (en) | 2014-02-14 | 2016-11-25 | 앤드류 에스. 카이 | Improved methods for the treatment of vascularizing cancers |
US9963509B2 (en) | 2014-12-23 | 2018-05-08 | Full Spectrum Genetics, Inc. | Anti-B7H3 binding compounds and uses thereof |
US10865245B2 (en) | 2014-12-23 | 2020-12-15 | Full Spectrum Genetics, Inc. | Anti-B7H3 binding compounds and uses thereof |
JP7320944B2 (en) | 2015-10-08 | 2023-08-04 | マクロジェニクス,インコーポレーテッド | Molecules that specifically bind to B7-H3 and molecules that specifically bind to PD-1 |
TWI781098B (en) | 2016-04-15 | 2022-10-21 | 美商宏觀基因股份有限公司 | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof |
MA52889A (en) | 2018-06-15 | 2021-04-21 | Flagship Pioneering Innovations V Inc | INCREASED IMMUNE ACTIVITY BY MODULATION OF POST-CELLULAR SIGNALING FACTORS |
WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
EP4022313A1 (en) | 2019-08-30 | 2022-07-06 | Y-Mabs Therapeutics, Inc. | Immunohistochemical assessment of b7-h3 expression |
EP4076434A1 (en) | 2019-12-17 | 2022-10-26 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
CN116096906A (en) | 2020-06-29 | 2023-05-09 | 旗舰创业创新五公司 | Virus engineered to promote saenox delivery and use thereof in treating cancer |
WO2022167052A1 (en) | 2021-02-08 | 2022-08-11 | Y-Mabs Therapeutics, Inc. | Use of ascorbic acid as stabilizing agent for anti b7-h3 antibodies |
US20220325287A1 (en) | 2021-03-31 | 2022-10-13 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
CA3224374A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1212344A4 (en) * | 1999-09-03 | 2004-08-04 | Human Genome Sciences Inc | B7-like polynucleotides, polypeptides, and antibodies |
AU2001283507A1 (en) * | 2000-07-27 | 2002-02-13 | Mayo Foundation For Medical Education And Research | B7-h3 and b7-h4, novel immunoregulatory molecules |
-
2001
- 2001-10-18 WO PCT/US2001/032565 patent/WO2002032375A2/en active Application Filing
- 2001-10-18 CA CA002423843A patent/CA2423843A1/en not_active Abandoned
- 2001-10-18 EP EP01983999A patent/EP1399187A4/en not_active Withdrawn
Non-Patent Citations (7)
Title |
---|
CANCER RES., vol. 60, no. 16, 15 August 2000 (2000-08-15), pages 4475 - 4476 * |
CANCER RES., vol. 61, no. 10, 15 May 2001 (2001-05-15), pages 4048 - 4049 * |
DATABASE PUBMED [online] XU ET AL.: "Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein", XP002908602, accession no. NCBI Database accession no. 10969795 * |
DATABASE PUBMED MODAK ET AL.: "Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors", XP002908601 * |
JUHL ET AL.: "Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells", IMMUNOBIOLOGY, vol. 197, November 1997 (1997-11-01), pages 444 - 459, XP002908499 * |
MODAK ET AL.: "Radioimmunotargeting to human rhabdomyosarcoma (RMS) using monoclonal antibody (MOAB) 8H9", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 41, March 2000 (2000-03-01), pages 724, ABSTRACT 4600, XP002908500 * |
See also references of EP1399187A4 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002032375A8 (en) | 2002-09-12 |
WO2002032375A9 (en) | 2003-01-03 |
CA2423843A1 (en) | 2002-04-25 |
EP1399187A2 (en) | 2004-03-24 |
EP1399187A4 (en) | 2005-09-21 |
WO2002032375A2 (en) | 2002-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002032375A8 (en) | Uses of monoclonal antibody 8h9 | |
WO2003075846A3 (en) | Uses of monoclonal antibody 8h9 | |
WO2002030986A3 (en) | HUMANIZED ANTI-LT-β-R ANTIBODIES | |
WO2002022851A3 (en) | Novel tumor-associated marker | |
WO2002030985A3 (en) | Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection | |
WO2001014424A3 (en) | Human ctla-4 antibodies and their uses | |
ATE412432T1 (en) | INTERNALIZING ERBB2 ANTIBODIES | |
EP1308455A3 (en) | A composition comprising anti-HER2 antibodies | |
AU4314900A (en) | Parenteral medicinal composition containing humanized monoclonal antibody fragment and method for stabilizing the same | |
WO2002016401A3 (en) | Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof | |
EP2336187B8 (en) | Compositions and methods of monoclonal and polyclonal antibodies specific for T cell subpopulations | |
EE05309B1 (en) | β-Am Looid Peptide "Humanized Antibodies, Method for Their Preparation, Their Use, and Pharmaceutical Composition | |
AU1462300A (en) | Human pan-hcv human monoclonal antibodies | |
AU6618100A (en) | Monoclonal antibodies to tacrolimus and immunoassay methods for tacrolimus | |
EP2186884A3 (en) | HCV-anti-core monoclonal antibody | |
WO2002075274A3 (en) | Method and kit for following neurodegenerative diseases | |
WO2003078468A3 (en) | Use of an active substance that binds to cd28 for producing a pharmaceutical composition | |
CA2348026A1 (en) | Antibodies against semp1, methods for their production and uses thereof | |
WO2002074251A3 (en) | Monoclonal antibody therapy for pancreas cancer | |
AU7960600A (en) | Monoclonal antibody, hybridoma, immunoassay method and diagnosis kit | |
AU2002359495A1 (en) | Anti-tnf antibodies, compositions, methods and uses | |
WO2002034290A3 (en) | Antibodies and other ligands directed against kir2dl4 receptor for production of interferon gamma | |
WO2003072727A3 (en) | EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER | |
AU2003283240A1 (en) | Antibody for isolating and/or identifying mesenchymal stem cells and method for isolating and/or identifying mesenchymal stem cells | |
AU2001280368A1 (en) | Use of anti-ceacam antibodies for stimulating b cells in the production of monoclonal antibodies or in immunotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
COP | Corrected version of pamphlet |
Free format text: PAGES 6-11, DESCRIPTION, REPLACED BY NEW PAGES 6-11; PAGES 1/32-32/32, DRAWINGS, REPLACED BY NEW PAGES 1/32-32/32; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2423843 Country of ref document: CA |
|
REEP | Request for entry into the european phase |
Ref document number: 2001983999 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001983999 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2001983999 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |